U.S., April 14 -- ClinicalTrials.gov registry received information related to the study (NCT07526558) titled 'Mast Cell Treatment in Post-tick Bite Illness (PTBI)' on April 06.
Brief Summary: This is a Phase II double-blinded study to assess the safety, tolerability, and feasibility of the mast cell stabilizing medications ketotifen and cromolyn compared to participants receiving standard of care treatment with fexofenadine alone in participants who have persistent symptoms of mast cell activation following a documented tick-borne illness (Ehrlichiosis, Rocky Mountain Spotted Fever, Alpha-gal Syndrome).
Study Start Date: April 30
Study Type: INTERVENTIONAL
Condition:
Post-tick Bite Illness
Mast Cell Stabilizer
Intervention:
DRUG: Ket...